Morphology of myeloproliferative neoplasms

被引:7
|
作者
Ng, Zi Yun [1 ,2 ]
Fuller, Kathryn A. [1 ]
Mazza-Parton, Allegra [1 ]
Erber, Wendy N. [1 ,3 ,4 ]
机构
[1] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia
[2] Royal Perth Hosp, Haematol Dept, Perth, WA, Australia
[3] PathWest Lab Med, Dept Haematol, Nedlands, WA, Australia
[4] Univ Western Australia, Sch Biomed Sci M504, Crawley, WA 6009, Australia
关键词
essential thrombocythaemia; myelofibrosis; myeloproliferative neoplasms; polycythaemia vera; BONE-MARROW FIBROSIS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; EUROPEAN CONSENSUS; MYELOFIBROSIS; MUTATIONS; DISEASE; JAK2; PROGRESSION; ANAGRELIDE;
D O I
10.1111/ijlh.14086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease progression. The blood film changes may be in any of the cellular elements. The key bone marrow features are architecture and cellularity, relative complement of individual cell types, reticulin content and bony structure. Megakaryocytes are the most abnormal cell and key to classification, as their number, location, size and cytology are all disease-defining. Reticulin content and grade are integral to assignment of the diagnosis of myelofibrosis. Even with careful assessment of all these features, not all cases fit neatly into the diagnostic entities; there is frequent overlap reflecting the biological disease continuum rather than distinct entities. Notwithstanding this, an accurate morphologic diagnosis in MPN is crucial due to the significant differences in prognosis between different subtypes and the availability of different therapies in the era of novel agents. The distinction between "reactive" and MPN is also not always straightforward and caution needs to be exercised given the prevalence of "triple negative" MPN. Here we describe the morphology of MPN including comments on changes with disease evolution and with treatment.
引用
收藏
页码:59 / 70
页数:12
相关论文
共 50 条
  • [41] MicroRNAs in myeloproliferative neoplasms
    Zhan, Huichun
    Cardozo, Christopher
    Raza, Azra
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (04) : 471 - 483
  • [42] Classification of myeloproliferative neoplasms and chronic myeloproliferative disorders
    Kreipe, Hans H.
    ONKOLOGE, 2019, 25 (11): : 957 - 970
  • [43] The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
    Orazi, A.
    Germing, U.
    LEUKEMIA, 2008, 22 (07) : 1308 - 1319
  • [44] The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
    A Orazi
    U Germing
    Leukemia, 2008, 22 : 1308 - 1319
  • [45] MORPHOLOGY OF MEGAKARYOCYTES AND STROMAL CHANGES BY BONE MARROW BIOPSY IN THE DIFFERENTIAL DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS
    Rodriguez Gonzalez, M.
    Moreno Carrasco, G.
    Garcia Munoz, I
    Prieto Cuadra, J. D.
    Garcia Delgado, R.
    HAEMATOLOGICA, 2019, 104 : 303 - 304
  • [46] Genetic complexity of myeloproliferative neoplasms
    Kralovics, R.
    LEUKEMIA, 2008, 22 (10) : 1841 - 1848
  • [47] Pathology Consultation on Myeloproliferative Neoplasms
    Schmidt, Amy E.
    Oh, Stephen T.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (01) : 12 - 19
  • [48] Focus on the epigenome in the myeloproliferative neoplasms
    Kim, Eunhee
    Abdel-Wahab, Omar
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 538 - 544
  • [49] Targeted therapies for myeloproliferative neoplasms
    Li, Bing
    Rampal, Raajit K.
    Xiao, Zhijian
    BIOMARKER RESEARCH, 2019, 7 (1)
  • [50] HYPERCALCEMIA AS A BIOMARKER OF MYELOPROLIFERATIVE NEOPLASMS?
    Langabeer, Stephen E.
    EXCLI JOURNAL, 2019, 18 : 777 - 778